Johnson & Johnson (JNJ)
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Both JNJ & PFE expect their sales and profits to improve in 2025.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Johnson & Johnson (JNJ) settling at $155.36, representing a +1.38% change from its previous close.
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.
S&P 500 Gains and Losses Today: Johnson & Johnson Drops as Judge Rejects Liability Settlement
Major U.S. equities indexes finished the first trading day of the second quarter mixed.
Why Johnson & Johnson Stock Is Sinking Today
Shares of Johnson & Johnson (JNJ -6.57%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m.
Johnson & Johnson shares fall as US judge rejects $10B talc settlement plan
Johnson & Johnson (NYSE:JNJ) shares moved almost 5% lower after a US bankruptcy judge rejected its $10 billion settlement proposal which sought to resolve tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer. Judge Christopher Lopez of the US Bankruptcy Court for the Southern District of Texas, Houston, dismissed the bankruptcy claim filed by J&J subsidiary Red River Talc, citing flaws in the voting process for personal injury claimants.
Judge rejects Johnson & Johnson's $10B settlement to end baby powder lawsuits
A judge rejected Johnson & Johnson's $10 billion proposal to end tens of thousands of lawsuits alleging that its products caused ovarian cancer.
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected
J&J fails in its third attempt to settle tens of thousands of lawsuits claiming its talc-based powder caused cancer.
J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan
Johnson & Johnson stock slumped Tuesday after a judge rejected its $10 billion proposal to settle thousands of talc-tied lawsuits. The post J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan appeared first on Investor's Business Daily.
Johnson & Johnson Latest Talc Resolution Rejected. The Stock Is Falling.
A bankruptcy judge in Texas rejected a proposal that would have ended most lawsuits saying the products cause ovarian cancer.
J&J shares fall after judge rejects $10 billion talc settlement
Johnson & Johnson shares fell more than 3% on Tuesday after a U.S. bankruptcy judge rejected its $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer.
US judge rejects J&J's $10 billion baby powder settlement
A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court.
